



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	09/849,969
				Filing Date	May 8, 2001
				First Named Inventor	Randolph J. Noelle
				Art Unit	1644
				Examiner Name	P. Gambel
Sheet	1	of	1	Attorney Docket Number	20052/1200521-US3

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Franco et al. (Apr. 1994) Eur. J. Immunol. vol. 24(4) 940-946.	
	CB	Mohan et al., Interaction Between CD50 and its Ligand GP39 in the Development of Murine Lupus Nephritis; Journal of Immunology. 1995; 154: 1471-79	
	CC	Staines et al., Collagen Arthritis-What Can it Teach Us? Br. J. Rheumatology. 1994; 33: 798-807	
	CD	Harris et al., Therapeutic Antibodies-the Coming of Age. 1993; Tibtech; 11: 42-44	
	CE	Durie et al., Antibody to Ligand of CD50, gp39, Blocks the Occurrence of the Acute and Chronic Forms of Graft-vs-Host Disease. J. Clin. Invest. 1994; 94: 1333-38.	
	CF	Queen et al., A Humanized Antibody that Binds to the Interleukin 2 Receptor. PNAS; 86: 10029-33	
	CG	Laman et al., The Role of GP39 (CD40 Ligand) in EAE and MS. J. Neuroimmunology. 1994; 54: 175	
	CH	Durie et al., Allogeneic Tolerance Induced by Treatment with an Antibody to the Ligand for CD40, GP39. Experimental Biology 94 Anaheim, CA April 24-28, 1994; Abstract 2763	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	6/6/05
-----------------------	--	--------------------	--------